<DOC>
	<DOCNO>NCT02892942</DOCNO>
	<brief_summary>To overcome unsuitable effect control ovarian hyperstimulation ( COH ) maintain large oocyte availability , investigator elaborate innovative protocol ( NATural Ovarian Stimulation ) dissociate E2 production multiple follicle development . The purpose prospective , randomized trial demonstrate , good prognosis IVF-ET population , physiological E2 environment result NATOS significantly improve IVF-ET outcome compare conventional GnRH antagonist protocol .</brief_summary>
	<brief_title>NATural Ovarian Stimulation</brief_title>
	<detailed_description>Controlled ovarian hyperstimulation ( COH ) seek improve IVF-ET result increase per-cycle oocyte embryo availability . Yet , coexistence multiple preovulatory follicle engenders compulsory alteration endocrine milieu follicular phase . The evident extremely high serum estradiol ( E2 ) level . The 10 15-fold increase E2 level result COH show provoke unwanted consequence embryo quality uterine receptivity . Therefore , investigator elaborate innovative COH protocol ( NATural Ovarian Stimulation ) aim dissociate E2 production multiple follicle development . To obtain effect , virtually curtail endogenous LH production use GnRH antagonist dose strong frequent enough maintain E2 level around physiological range standard exogenous FSH-only administration . Given high E2 level commonly reach patient normal follicle endowment , NATOS target group good prognosis IVF-ET candidate . Indeed , new COH approach first test pilot study include 15 good prognosis IVF-ET candidate , age 25-35 year , volunteer undergo NATOS . 11 15 patient achieved pregnancy . These pilot result spur conduct prospective , randomize trial demonstrate , good prognosis IVF-ET population , physiological E2 environment result NATOS significantly improve IVF-ET outcome compare conventional GnRH antagonist protocol .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Cetrorelix</mesh_term>
	<criteria>IVFET candidate ( exclude PGD oocyte donor ) ; Body mass index 18 30 kg/m2 ; Non smoker ; Regular menstrual cycle ( 2535 day ) ; Presence ovary ; Antral follicle count ( follicle measure 3 10 mm diameter ) range 10 24 cycle day 2 4 ; Serum AMH level range 1.2 4.0 ng/mL ; Normal endometrium ultrasound ( US ) and/or hysteroscopy ; Informed consent sign Iatrogenic ovarian insufficiency ( surgery , radiotherapy , chemotherapy ) ; Uterine abnormality demonstrate pelvic US and/or hysteroscopy ; Usual contraindication COH ( cancer risk , blood coagulation disorder , etc ) Renal insufficiency</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>36 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Controlled ovarian hyperstimulation</keyword>
	<keyword>Estradiol</keyword>
	<keyword>Embryo implantation</keyword>
	<keyword>Endometrial receptivity</keyword>
	<keyword>Fertility preservation</keyword>
</DOC>